# Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

> **NCT00802945** · PHASE2 · COMPLETED · sponsor: **Nektar Therapeutics** · enrollment: 70 (actual)

## Conditions studied

- Tumor
- Breast Cancer

## Interventions

- **DRUG:** NKTR-102
- **DRUG:** NKTR-102

## Key facts

- **NCT ID:** NCT00802945
- **Lead sponsor:** Nektar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-10
- **Final completion:** 2012-01
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2018-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00802945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00802945, "Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00802945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*